JP2010523156A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523156A5
JP2010523156A5 JP2010503183A JP2010503183A JP2010523156A5 JP 2010523156 A5 JP2010523156 A5 JP 2010523156A5 JP 2010503183 A JP2010503183 A JP 2010503183A JP 2010503183 A JP2010503183 A JP 2010503183A JP 2010523156 A5 JP2010523156 A5 JP 2010523156A5
Authority
JP
Japan
Prior art keywords
hsa
expression level
mir
risk score
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010503183A
Other languages
English (en)
Other versions
JP2010523156A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/059767 external-priority patent/WO2008124777A1/en
Publication of JP2010523156A publication Critical patent/JP2010523156A/ja
Publication of JP2010523156A5 publication Critical patent/JP2010523156A5/ja
Withdrawn legal-status Critical Current

Links

Description

さらに別の実施形態では、癌患者の治療後生存見込みは、上述の５つのマイクロＲＮＡの患者の発現レベルに基づいて予測することが可能である。リスクスコアは次のように計算される：（０．１５×ｈｓａ−ｍｉＲ１３７の発現レベル）＋（０．３１×ｈｓａ−ｍｉＲ３７２の発現レベル）＋（０．２８×ｈｓａ−ｍｉＲ−１８２＊の発現レベル）＋（−０．１３×ｈｓａ−ｍｉＲ２２１の発現レベル）＋（−０．１４×ｈｓａ−ｌｅｔ−７ａの発現レベル）。患者のリスクスコアが−７．１以下の場合、その癌患者は十分な治療後生存見込みを有する。
これらの５つのマイクロＲＮＡの発現レベルに基づいて、患者のリスクスコアを以下の式に従って計算した：（０．１５×発現レベルのｈｓａ−ｍｉＲ−１３７）＋（０．３１×発現レベルのｈｓａ−ｍｉＲ−３７２）＋（０．２８×発現レベルのｈｓａ−ｍｉＲ−１８２＊）＋（−０．１３×発現レベルのｈｓａ−ｍｉＲ−２２１）＋（０．１４×ｈｓａ−ｌｅｔ−７ａの発現レベル）。ハイリスクグループに−７．１より高いリスクスコアを有する患者はハイリスク群に割り当てられ、−７．１よりも低いリスクスコアを有する患者はローリスク群に割り当てられる。
JP2010503183A 2007-04-10 2008-04-09 マイクロｒｎａによる癌患者における治療後生存の予測 Withdrawn JP2010523156A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91099307P 2007-04-10 2007-04-10
PCT/US2008/059767 WO2008124777A1 (en) 2007-04-10 2008-04-09 Predicting post-treatment survival in cancer patients with micrornas

Publications (2)

Publication Number Publication Date
JP2010523156A JP2010523156A (ja) 2010-07-15
JP2010523156A5 true JP2010523156A5 (ja) 2010-09-16

Family

ID=39831416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010503183A Withdrawn JP2010523156A (ja) 2007-04-10 2008-04-09 マイクロｒｎａによる癌患者における治療後生存の予測

Country Status (13)

Country Link
US (1) US7745134B2 (ja)
EP (1) EP2134874A4 (ja)
JP (1) JP2010523156A (ja)
KR (1) KR20100027102A (ja)
CN (1) CN101688240A (ja)
AU (1) AU2008237036A1 (ja)
CA (1) CA2695868A1 (ja)
CO (1) CO6231056A2 (ja)
IL (1) IL201298A0 (ja)
MX (1) MX2009010899A (ja)
RU (1) RU2009141359A (ja)
TW (1) TWI367949B (ja)
WO (1) WO2008124777A1 (ja)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103866018B (zh) 2005-08-01 2016-05-25 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
CN101296702B (zh) 2005-09-12 2012-11-28 俄亥俄州立大学研究基金会 用于诊断或治疗bcl2相关癌症的组合物和方法
AU2007205257B2 (en) 2006-01-05 2013-07-25 The Ohio State University Research Foundation MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
ES2527592T3 (es) 2006-01-05 2015-01-27 The Ohio State University Research Foundation Métodos basados en microARN para el diagnóstico del cáncer de colon
EP2502630B1 (en) 2006-01-05 2015-03-11 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
AU2007227423B2 (en) 2006-03-20 2013-11-07 The Ohio State University Research Foundation MicroRNA fingerprints during human megakaryocytopoiesis
AU2007272947B2 (en) 2006-07-13 2013-06-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Micro-RNA-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
AU2007346101B2 (en) 2006-09-19 2013-08-15 The Ohio State University Research Foundation TCL1 expression in chronic lymphocytic leukemia (CLL) regulated by miR-29 and miR-181
CA2667617A1 (en) 2006-11-01 2008-05-08 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
WO2008094545A2 (en) 2007-01-31 2008-08-07 The Ohio State University Research Foundation Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
US8465917B2 (en) 2007-06-08 2013-06-18 The Ohio State University Research Foundation Methods for determining heptocellular carcinoma subtype and detecting hepatic cancer stem cells
CN101918424A (zh) 2007-06-15 2010-12-15 俄亥俄州立大学研究基金会 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白
CN101809169B (zh) 2007-07-31 2013-07-17 俄亥俄州立大学研究基金会 通过靶向dnmt3a和dnmt3b恢复甲基化的方法
US8465918B2 (en) 2007-08-03 2013-06-18 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
CA2926831A1 (en) 2007-08-22 2009-02-26 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
EP2201112A4 (en) 2007-10-26 2011-02-02 Univ Ohio State Res Found METHODS FOR IDENTIFYING INTERACTION OF THE "FRAGILE HISTIDINE TRIAD" GENE (FHIT) AND USES THEREOF
ES2433940T3 (es) 2008-06-11 2013-12-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Uso de la familia miR-26 como marcador predictivo del carcinoma hepatocelular y sensibilidad a la terapia
WO2010054386A2 (en) * 2008-11-10 2010-05-14 Battelle Memorial Institute Methods, compositions, and devices utilizing microrna to determine physiological conditions
WO2010065630A2 (en) * 2008-12-03 2010-06-10 The Johns Hopkins University Compositions and methods for treating hepatic neoplasia
EP2196543A1 (en) * 2008-12-15 2010-06-16 Koninklijke Philips Electronics N.V. Compositions and methods for micro-rna expression profiling of hepatocellular cancer
CN102272330B (zh) * 2009-02-23 2014-04-23 博奥生物有限公司 用于肺癌诊断、预后和提高生存率的试剂盒
CN101638656B (zh) * 2009-08-28 2011-05-11 南京医科大学 一种与非小细胞肺癌预后相关的血清/血浆miRNA标志物及其应用
CN102803511A (zh) 2009-11-23 2012-11-28 俄亥俄州立大学 用于影响肿瘤细胞生长、迁移和侵袭的材料和方法
ES2592386T3 (es) * 2009-12-20 2016-11-29 Astute Medical, Inc. Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
US20110223607A1 (en) 2010-03-12 2011-09-15 Quest Diagnostics Investments Incorporated Circulating microrna as a marker for hepatocellular carcinoma
WO2012065049A1 (en) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
CA2817982C (en) 2010-11-15 2020-06-30 The Regents Of The University Of Michigan Controlled release mucoadhesive systems
US8664192B2 (en) 2011-03-07 2014-03-04 The Ohio State University Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
US8404437B2 (en) 2011-03-29 2013-03-26 Taipei Veterans General Hospital MicroRNA as a cancer progression predictor and its use for treating cancer
WO2012151212A1 (en) * 2011-05-01 2012-11-08 University Of Rochester Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof
CN103857796A (zh) 2011-09-16 2014-06-11 Lsip基金运营联合公司 膀胱癌细胞的检测方法、用于膀胱癌细胞的检测方法的引物及膀胱癌标记物
JP2014530612A (ja) 2011-10-14 2014-11-20 ジ・オハイオ・ステート・ユニバーシティ 卵巣がんに関する方法および材料
CN104619353A (zh) 2011-12-13 2015-05-13 俄亥俄州国家创新基金会 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移
WO2013095941A1 (en) * 2011-12-19 2013-06-27 Valley Health System Methods and kits for detecting subjects at risk of having cancer
WO2013110053A1 (en) 2012-01-20 2013-07-25 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
US8846316B2 (en) 2012-04-30 2014-09-30 Industrial Technology Research Institute Biomarker for human liver cancer
US10738363B2 (en) 2016-08-31 2020-08-11 National Central University Analyzer and analytical method for predicting prognosis of cancer radiotherapy
DE102018110526A1 (de) 2018-05-02 2019-11-07 Faurecia Autositze Gmbh Verfahren zur Montage eines Linearaktuators für einen Kraftfahrzeugsitz
CN108647493B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 一种肾透明细胞癌个性化预后评估方法
CN108611416B (zh) * 2018-05-09 2020-12-29 中国科学院昆明动物研究所 一种基于多基因表达特征谱的宫颈癌个性化预后评估方法
CN108648826B (zh) * 2018-05-09 2022-04-15 中国科学院昆明动物研究所 一种基于多基因表达特征谱的胰腺癌个性化预后评估方法
CN108363907B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 一种基于多基因表达特征谱的肺腺癌个性化预后评估方法
CN108733980B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 基于多基因表达特征谱胶质母细胞瘤个性化预后评估方法
CN108320806B (zh) * 2018-05-09 2022-04-12 中国科学院昆明动物研究所 一种基于多基因表达特征谱的结肠癌个性化预后评估方法
CN108470111B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 一种基于多基因表达特征谱的胃癌个性化预后评估方法
CN108630317B (zh) * 2018-05-09 2022-04-15 中国科学院昆明动物研究所 一种基于多基因表达特征谱的肝癌个性化预后评估方法
US11410745B2 (en) * 2018-06-18 2022-08-09 International Business Machines Corporation Determining potential cancer therapeutic targets by joint modeling of survival events
TWI758670B (zh) * 2018-12-24 2022-03-21 奎克生技光電股份有限公司 健康風險評估方法
CN111172285A (zh) * 2020-02-26 2020-05-19 江南大学附属医院 用于胰腺癌早期诊断和/或预后监测的miRNA组及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006500074A (ja) * 2002-09-27 2006-01-05 オリディス・ビオメド・フォルシュングス−ウント・エントヴィックルングス・ゲーエムベーハー ポリペプチドおよびこれらをコード化する核酸ならびに肝臓障害および上皮癌の防止、診断、または処置のためのその使用
JP4939055B2 (ja) * 2002-11-13 2012-05-23 トマス ジェファソン ユニバーシティ 癌の診断および治療のための組成物および方法
CA2554818A1 (en) * 2004-02-09 2005-08-25 Thomas Jefferson University Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
US20050272067A1 (en) * 2004-03-10 2005-12-08 Macina Roberto A Compositions, splice variants and methods relating to cancer specific genes and proteins
US20060078913A1 (en) * 2004-07-16 2006-04-13 Macina Roberto A Compositions, splice variants and methods relating to cancer specific genes and proteins
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling

Similar Documents

Publication Publication Date Title
JP2010523156A5 (ja)
JP2014530874A5 (ja)
WO2008043521A3 (de) Microrna (mirna) zur diagnose und therapie von herzerkrankungen
NZ599298A (en) Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
MX2010001733A (es) Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.
EP2322650A8 (en) MicroRNAs and uses thereof
EP3042910A3 (en) 2'-spiro-nucleosides for use in the therapy of hepatitis c
JP2011500690A5 (ja)
JP2012092341A5 (ja)
BRPI0814737A2 (pt) Composição, métodos para reduzir, retardar ou de um outro modo inibir o crescimento e/ou replicação de hcv, para prevenir a infecção de uma célula exposta a hcv, para tratar terapeuticamente ou profilaticamente um paciente exposto ou infectado com hcv, e para tratar hepatite c, e, uso de uma composição.
JP2010280671A5 (ja)
EP2308885A3 (en) Novel compounds and methods for therapy
JP2009535462A5 (ja)
EP3059254A3 (en) A sulphated polysaccharide compound for the clinical use and the preparation and use thereof
WO2013048153A3 (ko) 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
JP2012505154A5 (ja)
EP3363454A3 (en) Treatment of diseases related to hyperactivity of the complement system
JP2012516348A5 (ja)
JP2008534621A5 (ja)
JP2011516572A5 (ja)
JP2012525422A5 (ja)
WO2012061811A3 (en) Anti- connective tissue growth factor agent for use in the treatment of lung remodeling disease
MX2010013019A (es) Sales antivirales.
JP2010526884A5 (ja)
EP2716758A8 (en) OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PHARMACEUTICAL COMPOSITION FOR DIAGNOSIS, AND OLIGONUCLEOTIDE DERIVATIVE FOR REGULATION OF miRNA FUNCTION